We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has recently been successfully tested in two Phase II studies. We work closely with academic teams in basic and clinical research. We use state-of-the-art analytical methods and develop our products according to the highest quality standards (GLP, GMP and GCP).
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Internationally (various countries)
A strong team
Well-known founders, convinced investors and research-strong employees: Together we are advanceCOR GmbH.
advanceCOR exists since June 2012 and emerged from Corimmun GmbH, which was sold to Janssen Cilag GmbH/Johnson & Johnson. The founding team includes well-known scientists, who still actively shape the course of advanceCOR today.
Prof. Dr. Götz Münch, internist and cardiologist, managing director of advanceCOR GmbH.
Prof. Dr. Martin Ungerer, internist and cardiologist, head of the medical division of ISAR Bioscience GmbH, member of the Translational Research Group of the German Centre for Cardiovascular Research (DZHK).
Prof. Dr. Meinrad Gawaz, Medical Director, Medical Clinic III, Department of Cardiology, University Hospital Tübingen.
Prof. Dr. Martin Lohse, Pharmacologist, University of Würzburg, Chairman of ISAR Bioscience GmbH and President of the German Society of Natural Scientists and Physicians (GDNÄ).
We are a small company with twenty competent, committed employees. Our scientists come from the fields of medicine, pharmacy, biology and chemistry and have a lot of experience in the biotech industry. We are convinced of our pipeline and do everything we can to bring it from research to the bedside.